Skip to main content

Advertisement

Table 2 Association of SII with clinicopathologic characteristics in patients with gastric cancer

From: Prognostic value of systemic immune-inflammation index in patients with gastric cancer

Characteristic SII < 660 [cases (%)] SII ≥ 660 [cases (%)] Χ 2 value P value
Total 283 161   
Sex    0.051 0.821
 Men 178 (62.9) 103 (64.0)   
 Women 105 (37.1) 58 (36.0)   
Age (years)    9.250 0.002
 <60 174 (61.5) 75 (46.6)   
 ≥60 109 (38.5) 86 (53.4)   
Tumor location    5.667 0.059
 Upper stomach 82 (29.0) 58 (36.0)   
 Middle stomach 83 (29.3) 54 (33.5)   
 Lower stomach 118 (41.7) 49 (30.4)   
Tumor size (cm)    20.867 <0.001
 <5 164 (58.0) 57 (35.4)   
 ≥5 119 (42.0) 104 (64.6)   
Pathologic type    4.642 0.326
 Adenocarcinoma 236 (83.4) 131 (81.4)   
 Squamous carcinoma 12 (4.2) 13 (8.1)   
 Adenosquamous carcinoma 3 (1.1) 0 (0.0)   
 Ring cell carcinoma 26 (9.2) 13 (8.1)   
 Undifferentiated carcinoma 6 (2.1) 4 (2.5)   
Borrmann classification    10.079 0.039
 1 15 (5.3) 15 (9.3)   
 2 74 (26.1) 24 (14.9)   
 3 161 (56.9) 98 (60.9)   
 4 28 (9.9) 22 (13.7)   
 5 5 (1.8) 2 (1.2)   
pT    23.504 <0.001
 1 46 (16.3) 7 (4.3)   
 2 30 (10.6) 11 (6.8)   
 3 115 (40.6) 60 (37.3)   
 4 92 (32.5) 83 (51.6)   
pN    12.925 0.005
 0 114 (40.3) 38 (23.6)   
 1 109 (38.5) 76 (47.2)   
 2 43 (15.2) 34 (21.1)   
 3 17 (6.0) 13 (8.1)   
pM    36.571 <0.001
 0 241 (85.2) 96 (59.6)   
 1 42 (14.8) 65 (40.4)   
TNM stage    40.848 <0.001
 I 62 (21.9) 15 (9.3)   
 II 47 (16.6) 17 (10.6)   
 III 132 (46.6) 64 (39.7)   
 IV 42 (14.8) 65 (40.4)   
CEA (μg/L)    4.778 0.029
 <5 261 (92.2) 138 (85.7)   
 ≥5 22 (7.8) 23 (14.3)   
NLR    52.974 <0.001
 <2.10 197 (69.6) 8 (5.0)   
 ≥2.10 86 (30.4) 153 (95.0)   
PLR    86.897 <0.001
 <120 137 (48.4) 7 (4.3)   
 ≥120 146 (51.6) 154 (95.7)   
  1. OS, overall survival; CI, confidence interval; CEA, carcinoembryonic antigen; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; SII, systemic immune-inflammation index